- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00015899
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the qualitative and quantitative toxicity of SCH 66336 in children with recurrent or progressive brain tumors.
- Estimate the maximum tolerated dose of this drug in these patients.
- Describe the pharmacokinetics of this drug with and without dexamethasone in these patients.
- Investigate the efficacy of this drug in these patients.
OUTLINE: This is a dose-escalation study.
Patients receive oral SCH 66336 twice daily. Treatment repeats every 4 weeks for a total of 26 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 1-6 patients receive escalating doses of SCH 66336 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which it is predicted that 20% of patients may experience dose-limiting toxicity. An additional 6 patients are treated at the determined MTD.
Patients are followed within 30 days of the last administration of the study drug and then for up to 3 months.
PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143-0372
- UCSF Comprehensive Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4318
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105-2794
- St. Jude Children's Research Hospital
-
-
Texas
-
Houston, Texas, United States, 77030-2399
- Texas Children's Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed recurrent or progressive (refractory) brain tumors
- Histologic confirmation waived for brainstem gliomas
- Bone marrow involvement allowed if transfusion independent
PATIENT CHARACTERISTICS:
Age:
- 21 and under
Performance status:
- Lansky 60-100% OR
- Karnofsky 60-100%
Life expectancy:
- More than 8 weeks
Hematopoietic:
- See Disease Characteristics
- Absolute neutrophil count greater than 1,000/mm^3
- Platelet count greater than 75,000/mm^3
- Hemoglobin greater than 9 g/dL
Hepatic:
- Bilirubin no greater than upper limit of normal
- SGPT and SGOT less than 2.5 times normal
- Albumin greater than 3 g/dL
- PT/PTT no greater than 120% upper limit of normal
- No overt hepatic disease
Renal:
- Creatinine no greater than 1.5 times normal OR
- Glomerular filtration rate greater than 70 mL/min
- No overt renal disease
Cardiovascular:
- No overt cardiac disease
Pulmonary:
- No overt pulmonary disease
Other:
- Neurologic deficits allowed if stable for at least 1 week prior to study
- More than 3rd percentile weight for height
- Able to swallow pills
- No uncontrolled infection
- No known or suspected allergy to poloxamer 188, croscarmellose sodium, silicon dioxide, or magnesium stearate I
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for up to 10 weeks after study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- More than 6 months since prior bone marrow transplantation
- More than 1 week since prior growth factors
Chemotherapy:
- At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
Endocrine therapy:
- Concurrent dexamethasone allowed if on stable dose for at least 1 week prior to study
- Concurrent oral contraceptives or other hormonal contraceptive methods allowed
Radiotherapy:
- More than 6 weeks since prior substantial bone marrow radiotherapy
- More than 3 months since prior craniospinal radiotherapy (more than 24 Gy) or total body irradiation
- More than 2 weeks since prior focal radiotherapy for symptomatic metastatic sites
Surgery:
- Not specified
Other:
- No concurrent enzyme-inducing anticonvulsant drugs
- No other concurrent anticancer or experimental drug therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicities of SCH 66336 in children and adolescents with refractory CNS cancers
|
|
Maximum tolerated dose of SCH 66336
Time Frame: Four weeks
|
Four weeks
|
Pharmacokinetics of SCH 66336
|
Secondary Outcome Measures
Outcome Measure |
---|
Tumor response to SCH 66336
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Mark W. Kieran, MD, PhD, Dana-Farber Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- childhood atypical teratoid/rhabdoid tumor
- childhood oligodendroglioma
- recurrent childhood cerebellar astrocytoma
- recurrent childhood cerebral astrocytoma
- recurrent childhood ependymoma
- recurrent childhood medulloblastoma
- recurrent childhood visual pathway and hypothalamic glioma
- childhood craniopharyngioma
- childhood central nervous system germ cell tumor
- childhood choroid plexus tumor
- childhood grade I meningioma
- childhood grade II meningioma
- childhood grade III meningioma
- childhood spinal cord neoplasm
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000068571
- PBTC-003
- SPRI-P02201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain and Central Nervous System Tumors
-
Children's Hospital Los AngelesUnknownBrain and Central Nervous System TumorsUnited States, Canada, Australia, Switzerland, New Zealand
-
Emory UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedVNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsBrain and Central Nervous System TumorsUnited States
-
St. Jude Children's Research HospitalCompletedBrain Tumors | Central Nervous System TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumors | Central Nervous System TumorsUnited States, Australia, Canada
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors
Clinical Trials on lonafarnib
-
Merck Sharp & Dohme LLCTerminatedMetastases, Neoplasm | Carcinoma, Non-small-cell Lung
-
Merck Sharp & Dohme LLCTerminatedBreast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnColorectal Cancer | Metastatic Cancer
-
European Organisation for Research and Treatment...UnknownBrain and Central Nervous System TumorsSwitzerland, France
-
Boston Children's HospitalEnrolling by invitation
-
M.D. Anderson Cancer CenterCompletedChronic Myelogenous LeukemiaUnited States
-
Eiger BioPharmaceuticalsApproved for marketing
-
M.D. Anderson Cancer CenterCompletedMyelogenous Leukemia, ChronicUnited States
-
Monica E. KleinmanSchering-PloughCompletedProgeria | Hutchinson-Gilford SyndromeUnited States
-
National Institute of Diabetes and Digestive and...Completed